Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib

BACKGROUND: Mitogen-activated protein kinase kinase (MEK) inhibitor cobimetinib and V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor vemurafenib have significantly improved the prognosis of BRAF-mutated metastatic melanoma. Some ocular symptoms and signs were recently recognized to fo...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Radiol Oncol
Asıl Yazarlar: Gavric, Ana Ursula, Ocvirk, Janja, Mekjavic, Polona Jaki
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Sciendo 2018
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6043881/
https://ncbi.nlm.nih.gov/pubmed/30018526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2478/raon-2018-0002
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller